Amplia Therapeutics (ASX:ATX) Cash-to-Debt : 2.53 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Amplia Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2023 was 2.53.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Amplia Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Amplia Therapeutics's Cash-to-Debt or its related term are showing as below:

ASX:ATX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.53 Med: No Debt Max: No Debt
Current: 2.53

During the past 10 years, Amplia Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.53. And the median was No Debt.

ASX:ATX's Cash-to-Debt is ranked worse than
64.09% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs ASX:ATX: 2.53

Amplia Therapeutics Cash-to-Debt Historical Data

The historical data trend for Amplia Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Amplia Therapeutics Cash-to-Debt Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

112.82

No Debt

6.96

4.07

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	6.96	5.06	4.07	2.53

Competitive Comparison of Amplia Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Amplia Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Cash-to-Debt falls into.

Amplia Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Amplia Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.257	/	(2.181	+	0.095)
	=	4.07

Amplia Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.657	/	(2.185	+	0.055)
	=	2.53

Amplia Therapeutics (ASX:ATX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Amplia Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (ASX:ATX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

INNMF:USA

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines